Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minzasolmin extension study in new-onset Parkinson's disease
NL-OMON59944Phase 2Completed
- Sponsor
- UCB
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of minzasolmin in Parkinson's disease (PD) (2 arms), sponsored by UCB. Primary endpoint: Baseline-adjusted DaT-SPECT whole striatum specific binding ratio at Month 18. Started Feb 2023; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59944.